{
  "docId": "019de075-cd17-7685-9273-fb1c731af40f",
  "docSlug": "16b2d7592f4634ac7cd717a996934f07",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 35,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide outlines a clinical trial design using a randomized withdrawal methodology.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/15",
  "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f",
  "deckJsonHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f.json",
  "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "callout",
      "text": "High Probability of Technical Success",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3acb735c-a9a1-4b9d-a5f4-eba752ec3b49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.6,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "diagram",
      "text": "Open-Label 12 weeks followed by Double-blind RWD 8 weeks",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16aafba1-1d03-4a98-a149-c6a47fc66a86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Enrichment Strategies for Clinical Trials to Support Determination of Effectiveness of Human Drugs and Biological Products Guidance for Industry",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6380920-30c8-489e-8237-4661c6d912a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.7,
        "y": 0.4
      },
      "kind": "list",
      "text": "CYPRESS KEYS: Primary Endpoint, Optimized Duration, Aligned with FDA",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59dd0e8d-3538-48c1-8073-f9b77eff31e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "CYPRESS: Phase 3 randomized withdrawal (RWD) study in patients with MSA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65d4d668-9a98-4a29-a9ee-e4a003ae24db",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "ddf1ccd6-2bd7-4bd7-b530-e1ad73d11b19",
      "evidence": "The slide has a clear call-to-action and attention-grabbing elements.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "f8467e5f-9851-4fdc-8bbb-ded4acd6ec61",
      "evidence": "The timeline visualization of the clinical trial phases.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 18,
      "from": 11,
      "beatId": "ae4646ce-73d8-418d-9390-888b787632a7",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document presents the company's progress and potential for YUPELRI and Ampreloxetine",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 17,
      "from": 10,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f11bf40d-c1c5-42f1-a514-3da6d8f2856f",
      "evidence": "The document highlights the significant unmet need for MSA patients",
      "position": 1,
      "objective": "Emphasizing the cost of inaction for MSA patients",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}